These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7131442)

  • 1. The effects of progestins on vasomotor flushes.
    Schiff I
    J Reprod Med; 1982 Aug; 27(8 Suppl):498-502. PubMed ID: 7131442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The menopause: benefits and risks of estrogen-progestogen replacement therapy.
    Gambrell RD
    Fertil Steril; 1982 Apr; 37(4):457-74. PubMed ID: 7040116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex steroids and breast cancer prevention.
    Spicer DV; Pike MC
    J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical use of progestins in the menopausal patient: dosage and duration.
    Gambrell RD
    J Reprod Med; 1982 Aug; 27(8 Suppl):531-8. PubMed ID: 7131446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologic and pharmacologic effects of estrogen and progestins on bone.
    DeCherney A
    J Reprod Med; 1993 Dec; 38(12 Suppl):1007-14. PubMed ID: 8120857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
    Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
    Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone replacement therapy and estrogen-dependent cancers.
    Birkhäuser M
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():99-114. PubMed ID: 7874193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestin replacement in the menopause: effects on the endometrium and serum lipids.
    Williams DB; Moley KH
    Curr Opin Obstet Gynecol; 1994 Jun; 6(3):284-92. PubMed ID: 8038417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy and risk of breast cancer: the role of progestins.
    Stahlberg C; Pedersen AT; Lynge E; Ottesen B
    Acta Obstet Gynecol Scand; 2003 Apr; 82(4):335-44. PubMed ID: 12716318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HRT dosing regimens: continuous versus cyclic-pros and cons.
    Shoupe D
    Int J Fertil Womens Med; 2001; 46(1):7-15. PubMed ID: 11294619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasomotor symptoms and estrogen-progestogen therapy.
    von Schoultz B
    Acta Obstet Gynecol Scand Suppl; 1985; 132():15-8. PubMed ID: 3161264
    [No Abstract]   [Full Text] [Related]  

  • 15. Progestins and breast cancer risk.
    Campagnoli C; Biglia N; Giai M; Sismondi P
    Zentralbl Gynakol; 1997; 119 Suppl 2():38-42. PubMed ID: 9361393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
    Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
    Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
    Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of medroxyprogesterone acetate to prevent menopausal symptoms.
    Bullock JL; Massey FM; Gambrell RD
    Obstet Gynecol; 1975 Aug; 46(2):165-8. PubMed ID: 1153148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cancer risk under hormone therapy].
    Lauritzen C
    Ther Umsch; 1994 Nov; 51(11):755-66. PubMed ID: 7839334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral contraception and its beneficial gynecological effects].
    Belaisch J; Hommais-loufrani B
    Fertil Contracept Sex; 1988 Mar; 16(3 Suppl):3-7. PubMed ID: 12282188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.